Drug Discovery

Boehringer Ingelheim's Nerandomilast Shows Promise in Treating PPF
Research & Development Boehringer Ingelheim's Nerandomilast Shows Promise in Treating PPF

Boehringer Ingelheim has made significant strides in their research on progressive pulmonary fibrosis (PPF) with the successful results of their Phase III FIBRONEER™-ILD trial. This trial marks a critical milestone for Nerandomilast, an investigational oral preferential inhibitor of p

Can Zai Lab's ZL-1310 Revolutionize Small Cell Lung Cancer Treatment?
Research & Development Can Zai Lab's ZL-1310 Revolutionize Small Cell Lung Cancer Treatment?

The recent Orphan Drug Designation (ODD) granted by the U.S. Food and Drug Administration (FDA) to Zai Lab Limited for their drug ZL-1310 marks a significant milestone in the fight against small cell lung cancer (SCLC). This promising Delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC) is

Allarity Therapeutics Expands Phase 2 Trial of Stenoparib for Ovarian Cancer
Research & Development Allarity Therapeutics Expands Phase 2 Trial of Stenoparib for Ovarian Cancer

Allarity Therapeutics, Inc. has announced the expansion of their Phase 2 clinical trial for stenoparib, a dual PARP/Wnt pathway inhibitor, aimed at treating advanced ovarian cancer. Their recent decision seeks to accelerate the drug's clinical development and work towards FDA regulatory

Enhancing Clinical Trial Enrollment and Retention with Technology
Research & Development Enhancing Clinical Trial Enrollment and Retention with Technology

Clinical trials are fundamental to the development of new medical treatments and the advancement of healthcare. However, enrolling and retaining participants in these trials has been a persistent challenge over the years. The perceived difficulty of involvement, alongside high dropout rates, can

Unlocking the Potential of Value-Added Medicines in Modern Healthcare
Research & Development Unlocking the Potential of Value-Added Medicines in Modern Healthcare

The 21st century has seen the pharmaceutical industry face mounting challenges such as escalating competition and pricing pressures. Consequently, developers and manufacturers are pioneering innovative strategies to differentiate their products and instill value, particularly in the saturated

How is Healthcare Investment Evolving in 2024's Dynamic Landscape?
Management & Regulatory How is Healthcare Investment Evolving in 2024's Dynamic Landscape?

The healthcare investment landscape has undergone significant transformations in recent years, driven by various factors including the COVID-19 pandemic, technological advancements, and strategic shifts within the industry. As we delve into 2024, it is crucial to understand the key trends and

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later